References
- Mundt AJ, Vijayakumar S, Nemunaitis J, Sandler A, Schwartz H, Hanna N, Peabody T, Senzer N, Chu K, Rasmussen CS, Kessler PD, Rasmussen HS, Warso M, Kufe DW, Gupta TD, Weichselbaum RR. A Phase I trial of TNFerade biologic in patients with soft tissue sarcoma in the extremities.2004;: 5747-53.
- Manome Y, Kunieda T, Wen PY, Koga T, Kufe DW, Ohno T. Transgene expression in malignant glioma using a replication-defective adenoviral vector containing the Egr-1 promoter: activation by ionizing radiation or uptake of radioactive iododeoxyuridine.1998;: 1409-17.
- Weichselbaum RR, Hallahan DE, Beckett MA, Mauceri HJ, Lee H, Sukhatme VP, Kufe DW. Gene therapy targeted by radiation preferentially radiosensitizes tumor cells.1994;: 4266-9.
- Hallahan DE, Mauceri HJ, Seung LP, Dunphy EJ, Wayne JD, Hanna NN, Toledano A, Hellman S, Kufe DW, Weichselbaum RR. Spatial and temporal control of gene therapy using ionizing radiation.1995;: 786-91.
- Chung TD, Mauceri HJ, Hallahan DE, Yu JJ, Chung S, Grdina WL, Yajnik S, Kufe DW, Weichselbaum RR. Tumor necrosis factor-alpha-based gene therapy enhances radiation cytotoxicity in human prostate cancer.1998;: 344-9.
- Gupta VK, Park JO, Jaskowiak NT, Mauceri HJ, Seetharam S, Weichselbaum RR, Posner MC. Combined gene therapy and ionizing radiation is a novel approach to treat human esophageal adenocarcinoma.2002;: 500-4.
- Weichselbaum RR, Kufe DW, Hellman S, Rasmussen HS, King CR, Fischer PH, Mauceri HJ. Radiation-induced tumour necrosis factor-alpha expression: clinical application of transcriptional and physical targeting of gene therapy.2002;: 665-71.
- Rasmussen H, Rasmussen C, Lempicki M, Durham R, Brough D, King CR, Weichselbaum R. TNFerade Biologic: preclinical toxicology of a novel adenovector with a radiation-inducible promoter, carrying the human tumor necrosis factor alpha gene.2002;: 951-7.
- Senzer N, Mani S, Rosemurgy A, Nemunaitis J, Cunningham C, Guha C, Bayol N, Gillen M, Chu K, Rasmussen C, Rasmussen H, Kufe D, Weichselbaum R, Hanna N. TNFerade biologic, an adenovector with a radiation-inducible promoter, carrying the human tumor necrosis factor alpha gene: a phase I study in patients with solid tumors.2004;: 592-601.
- Salloum RM, Saunders MP, Mauceri HJ, Hanna NN, Gorski DH, Posner MC, Stratford IJ, Weichselbaum RR. Dual induction of the Epo-Egr-TNF-alpha-plasmid in hypoxic human colon adenocarcinoma produces tumor growth delay.2003;: 24-7.
- Scott SD, Marples B, Hendry JH, Lashford LS, Embleton MJ, Hunter RD, Howell A, Margison GP. A radiation-controlled molecular switch for use in gene therapy of cancer.2000;: 1121-5.
- Bernier J, Hall EJ, Giaccia A. Radiation oncology: a century of achievements.2004;: 737-47.
- Tubiana M, Eschwege F. Conformal radiotherapy and intensity-modulated radiotherapy-clinical data.2000;: 555-67.
- Shinohara ET, Lu B, Hallahan DE. The use of gene therapy in cancer research and treatment.2004;: 479-90.
- Gridley DS, Slater JM. Combining gene therapy and radiation against cancer.2004;: 231-48.
- Robson T, Worthington J, McKeown SR, Hirst DG. Radiogenic therapy: novel approaches for enhancing tumor radiosensitivity.2005;: 343-61.
- Lumniczky K, Safrany G. Cancer gene therapy: combination with radiation therapy and the role of bystander cell killing in the anti-tumor effect.2006;: 118-24.
- Stevens CW, Zeng M, Cerniglia GJ. Ionizing radiation greatly improves gene transfer efficiency in mammalian cells.1996;: 1727-34.
- Zeng M, Cerniglia GJ, Eck SL, Stevens CW. High-efficiency stable gene transfer of adenovirus into mammalian cells using ionizing radiation.1997;: 1025-32.
- Sonveaux P, Dessy C, Brouet A, Jordan BF, Gregoire V, Gallez B, Balligand JL, Feron O. Modulation of the tumor vasculature functionality by ionizing radiation accounts for tumor radiosensitization and promotes gene delivery.2002;: 1979-81.
- Weichselbaum RR, Hallahan DE, Sukhatme VP, Kufe DW. Gene therapy targeted by ionizing radiation.1992;: 565-7.
- Sersa G, Miklavcic D, Rudolf Z, Cemazar M, Pucihar G, Snoj M. Electrochemotherapy in treatment of tumours.2008;: 232-240.
- Wardman P. Chemical radiosensitizers for use in radiotherapy.2007;: 397-417.
- Kufe D, Weichselbaum R. Radiation therapy: activation for gene transcription and the development of genetic radiotherapy-therapeutic strategies in oncology.2003;: 326-9.
- Greco O, Dachs GU. Gene directed enzyme/prodrug therapy of cancer: historical appraisal and future prospectives.2001;: 22-36.
- Dachs GU, Tupper J, Tozer GM. From bench to bedside for gene-directed enzyme prodrug therapy of cancer.2005;: 349-59.
- McKeown SR, Ward C, Robson T. Gene-directed enzyme prodrug therapy: a current assessment.2004;: 421-35.
- Greco O, Marples B, Dachs GU, Williams KJ, Patterson AV, Scott SD. Novel chimeric gene promoters responsive to hypoxia and ionizing radiation.2002;: 1403-11.
- Khil MS, Kim JH, Mullen CA, Kim SH, Freytag SO. Radiosensitization by 5-fluorocytosine of human colorectal carcinoma cells in culture transduced with cytosine deaminase gene.1996;: 53-7.
- Rogulski KR, Zhang K, Kolozsvary A, Kim JH, Freytag SO. Pronounced antitumor effects and tumor radiosensitization of double suicide gene therapy.1997;: 2081-8.
- Xia K, Liang D, Tang A, Feng Y, Zhang J, Pan Q, Long Z, Dai H, Cai F, Wu L, Zhao S, Chen Z, Xia J. A novel fusion suicide gene yeast CDglyTK plays a role in radio-gene therapy of nasopharyngeal carcinoma.2004;: 790-6.
- Freytag SO, Paielli D, Wing M, Rogulski K, Brown S, Kolozsvary A, Seely J, Barton K, Dragovic A, Kim JH. Efficacy and toxicity of replication-competent adenovirus-mediated double suicide gene therapy in combination with radiation therapy in an orthotopic mouse prostate cancer model.2002;: 873-85.
- Freytag SO, Khil M, Stricker H, Peabody J, Menon M, Peralta-Venturina M, Nafziger D, Pegg J, Paielli D, Brown S, Barton K, Lu M, guilar-Cordova E, Kim JH. Phase I study of replication-competent adenovirus-mediated double suicide gene therapy for the treatment of locally recurrent prostate cancer.2002;: 4968-76.
- Mitchell JB, Wink DA, DeGraff W, Gamson J, Keefer LK, Krishna MC. Hypoxic mammalian cell radiosensitization by nitric oxide.1993;: 5845-8.
- Kurimoto M, Endo S, Hirashima Y, Hamada H, Ogiichi T, Takaku A. Growth inhibition and radiosensitization of cultured glioma cells by nitric oxide generating agents.1999;: 35-44.
- Wang Z, Cook T, Alber S, Liu K, Kovesdi I, Watkins SK, Vodovotz Y, Billiar TR, Blumberg D. Adenoviral gene transfer of the human inducible nitric oxide synthase gene enhances the radiation response of human colorectal cancer associated with alterations in tumor vascularity.2004;: 1386-95.
- Jordan BF, Misson P, Demeure R, Baudelet C, Beghein N, Gallez B. Changes in tumor oxygenation/perfusion induced by the no donor, isosorbide dinitrate, in comparison with carbogen: monitoring by EPR and MRI.2000;: 565-70.
- Worthington J, Robson T, O'Keeffe M, Hirst DG. Tumour cell radiosensitization using constitutive (CMV) and radiation inducible (WAF1) promoters to drive the iNOS gene: a novel suicide gene therapy.2002;: 263-9.
- Xie K, Huang S, Dong Z, Juang SH, Gutman M, Xie QW, Nathan C, Fidler IJ. Transfection with the inducible nitric oxide synthase gene suppresses tumorigenicity and abrogates metastasis by K-1735 murine melanoma cells.1995;: 1333-43.
- Worthington J, McCarthy HO, Barrett E, Adams C, Robson T, Hirst DG. Use of the radiation-inducible WAF1 promoter to drive iNOS gene therapy as a novel anti-cancer treatment.2004;: 673-80.
- Worthington J, Robson T, Scott S, Hirst D. Evaluation of a synthetic CArG promoter for nitric oxide synthase gene therapy of cancer.2005;: 1417-23.
- Cook T, Wang Z, Alber S, Liu K, Watkins SC, Vodovotz Y, Billiar TR, Blumberg D. Nitric oxide and ionizing radiation synergistically promote apoptosis and growth inhibition of cancer by activating p53.2004;: 8015-21.
- Tangney M, Casey G, Larkin JO, Collins CG, Soden D, Cashman J, Whelan MC, O'Sullivan GC. Non-viral in vivo immune gene therapy of cancer: combined strategies for treatment of systemic disease.2006;: 1443-50.
- Friedman EJ. Immune modulation by ionizing radiation and its implications for cancer immunotherapy.2002;: 1765-80.
- Demaria S, Bhardwaj N, McBride WH, Formenti SC. Combining radiotherapy and immunotherapy: a revived partnership.2005;: 655-66.
- Tuting T, Storkus WJ, Lotze MT. Gene-based strategies for the immunotherapy of cancer.1997;: 478-91.
- Li CY, Huang Q, Kung HF. Cytokine and immuno-gene therapy for solid tumors.2005;: 81-91.
- Ulmer JB, Donnelly JJ, Liu MA. Toward the development of DNA vaccines.1996;: 653-8.
- Stevenson FK, Ottensmeier CH, Johnson P, Zhu D, Buchan SL, McCann KJ, Roddick JS, King AT, McNicholl F, Savelyeva N, Rice J. DNA vaccines to attack cancer.2004;: 14646-52.
- Hodge JW, Greiner JW, Tsang KY, Sabzevari H, Kudo-Saito C, Grosenbach DW, Gulley JL, Arlen PM, Marshall JL, Panicali D, Schlom J. Costimulatory molecules as adjuvants for immunotherapy.2006;: 788-803.
- Chakraborty M, Abrams SI, Coleman CN, Camphausen K, Schlom J, Hodge JW. External beam radiation of tumors alters phenotype of tumor cells to render them susceptible to vaccine-mediated T-cell killing.2004;: 4328-37.
- Gulley JL, Arlen PM, Bastian A, Morin S, Marte J, Beetham P, Tsang KY, Yokokawa J, Hodge JW, Menard C, Camphausen K, Coleman CN, Sullivan F, Steinberg SM, Schlom J, Dahut W. Combining a recombinant cancer vaccine with standard definitive radiotherapy in patients with localized prostate cancer.2005;: 3353-62.
- Miller AR, McBride WH, Hunt K, Economou JS. Cytokine-mediated gene therapy for cancer.1994;: 436-50.
- Kemeny N, Childs B, Larchian W, Rosado K, Kelsen D. A phase II trial of recombinant tumor necrosis factor in patients with advanced colorectal carcinoma.1990;: 659-63.
- Hallahan DE, Vokes EE, Rubin SJ, O'Brien S, Samuels B, Vijaykumar S, Kufe DW, Phillips R, Weichselbaum RR. Phase I dose-escalation study of tumor necrosis factor-alpha and concomitant radiation therapy.1995;: 204-9.
- Trinchieri G. Interleukin-12: a proinflammatory cytokine with immunoregulatory functions that bridge innate resistance and antigen-specific adaptive immunity.1995;: 251-76.
- Trinchieri G. Interleukin-12 and the regulation of innate resistance and adaptive immunity.2003;: 133-46.
- Voest EE, Kenyon BM, O'Reilly MS, Truitt G, D'Amato RJ, Folkman J. Inhibition of angiogenesis in vivo by interleukin 12.1995;: 581-6.
- Ogawa M, Yu WG, Umehara K, Iwasaki M, Wijesuriya R, Tsujimura T, Kubo T, Fujiwara H, Hamaoka T. Multiple roles of interferon-gamma in the mediation of interleukin 12-induced tumor regression.1998;: 2426-32.
- Brunda MJ, Luistro L, Warrier RR, Wright RB, Hubbard BR, Murphy M, Wolf SF, Gately MK. Antitumor and antimetastatic activity of interleukin 12 against murine tumors.1993;: 1223-30.
- Seetharam S, Staba MJ, Schumm LP, Schreiber K, Schreiber H, Kufe DW, Weichselbaum RR. Enhanced eradication of local and distant tumors by genetically produced interleukin-12 and radiation.1999;: 769-73.
- Lohr F, Hu K, Haroon Z, Samulski TV, Huang Q, Beaty J, Dewhirst MW, Li CY. Combination treatment of murine tumors by adenovirus-mediated local B7/IL12 immunotherapy and radiotherapy.2000;: 195-203.
- Xian J, Yang H, Lin Y, Liu S. Combination nonviral murine interleukin 2 and interleukin 12 gene therapy and radiotherapy for head and neck squamous cell carcinoma.2005;: 1079-85.
- Fujita T, Timme TL, Tabata K, Naruishi K, Kusaka N, Watanabe M, Abdelfattah E, Zhu JX, Ren C, Ren C, Yang G, Goltsov A, Wang H, Vlachaki MT, Teh BS, Butler EB, Thompson TC. Cooperative effects of adenoviral vector-mediated interleukin 12 gene therapy with radiotherapy in a preclinical model of metastatic prostate cancer.2007;: 227-36.
- Yang Y, Liu SZ, Fu SB. Anti-tumor effects of pNEgr-mIL-12 recombinant plasmid induced by X-irradiation and its mechanisms.2004;: 135-43.
- van HR, ten Hagen TL, Eggermont AM. TNF-alpha in cancer treatment: molecular insights, antitumor effects, and clinical utility.2006;: 397-408.
- Sersa G, Willingham V, Milas L. Anti-tumor effects of tumor necrosis factor alone or combined with radiotherapy.1988;: 129-34.
- U. S. National Institutes of Health (Internet). Retrieved March 2008, from:
- Mauceri HJ, Hanna NN, Wayne JD, Hallahan DE, Hellman S, Weichselbaum RR. Tumor necrosis factor alpha (TNF-alpha) gene therapy targeted by ionizing radiation selectively damages tumor vasculature.1996;: 4311-4.
- Brem S, Brem H, Folkman J, Finkelstein D, Patz A. Prolonged tumor dormancy by prevention of neovascularization in the vitreous.1976;: 2807-12.
- Hanahan D, Weinberg RA. The hallmarks of cancer.2000;: 57-70.
- Denekamp J. Review article: angiogenesis, neovascular proliferation and vascular pathophysiology as targets for cancer therapy.1993;: 181-96.
- Folkman J, Hanahan D. Switch to the angiogenic phenotype during tumorigenesis.1991;: 339-47.
- Hanahan D, Folkman J. Patterns and emerging mechanisms of the angiogenic switch during tumorigenesis.1996;: 353-64.
- Bergers G, Benjamin LE. Tumorigenesis and the angiogenic switch.2003;: 401-10.
- Boehm T, Folkman J, Browder T, O'Reilly MS. Antiangiogenic therapy of experimental cancer does not induce acquired drug resistance.1997;: 404-7.
- Folkman J. Angiogenesis in cancer, vascular, rheumatoid and other disease.1995;: 27-31.
- Wachsberger P, Burd R, Dicker AP. Tumor response to ionizing radiation combined with antiangiogenesis or vascular targeting agents: exploring mechanisms of interaction.2003;: 1957-71.
- Scappaticci FA. Mechanisms and future directions for angiogenesis-based cancer therapies.2002;: 3906-27.
- Siemann DW, Warrington KH, Horsman MR. Targeting tumor blood vessels: an adjuvant strategy for radiation therapy.2000;: 5-12.
- Siemann DW, Bibby MC, Dark GG, Dicker AP, Eskens FA, Horsman MR, Marme D, Lorusso PM. Differentiation and definition of vascular-targeted therapies.2005;: 416-20.
- Kong HL, Crystal RG. Gene therapy strategies for tumor antiangiogenesis.1998;: 273-86.
- O'Reilly MS. Angiostatin: an endogenous inhibitor of angiogenesis and of tumor growth.1997;: 273-94.
- Folkman J. Antiangiogenic gene therapy.1998;: 9064-6.
- Tandle A, Blazer DG, III, Libutti SK. Antiangiogenic gene therapy of cancer: recent developments.2004;: 22.
- O'Reilly MS. Radiation combined with antiangiogenic and antivascular agents.2006;: 45-50.
- Jain RK. Normalizing tumor vasculature with anti-angiogenic therapy: a new paradigm for combination therapy.2001;: 987-9.
- Siemann DW, Chaplin DJ, Horsman MR. Vascular-targeting therapies for treatment of malignant disease.2004;: 2491-9.
- Wahl ML, Moser TL, Pizzo SV. Angiostatin and anti-angiogenic therapy in human disease.2004;73-104.
- Folkman J. Antiangiogenesis in cancer therapy-endostatin and its mechanisms of action.2006;: 594-607.
- Shi W, Teschendorf C, Muzyczka N, Siemann DW. Gene therapy delivery of endostatin enhances the treatment efficacy of radiation.2003;: 1-9.
- Zheng AQ, Song XR, Yu JM, Wei L, Wang XW. Liposome transfected to plasmid-encoding endostatin gene combined with radiotherapy inhibits liver cancer growth in nude mice.2005;: 4439-42.
- Luo X, Slater JM, Gridley DS. Enhancement of radiation effects by pXLG-mEndo in a lung carcinoma model.2005;: 553-64.
- Griscelli F, Li H, Cheong C, Opolon P, naceur-Griscelli A, Vassal G, Soria J, Soria C, Lu H, Perricaudet M, Yeh P. Combined effects of radiotherapy and angiostatin gene therapy in glioma tumor model.2000;: 6698-703.
- ten Hagen TL, Eggermont AM. Solid tumor therapy: manipulation of the vasculature with TNF.2003;: 195-203.
- Menon C, Ghartey A, Canter R, Feldman M, Fraker DL. Tumor necrosis factor-alpha damages tumor blood vessel integrity by targeting VE-cadherin.2006;: 781-91.
- Weichselbaum RR, Kufe DW, Advani SJ, Roizman B. Molecular targeting of gene therapy and radiotherapy.2001;: 735-8.
- Robson T, Hirst DG. Transcriptional Targeting in Cancer Gene Therapy.2003;: 110-37.
- Dachs GU, Dougherty GJ, Stratford IJ, Chaplin DJ. Targeting gene therapy to cancer: a review.1997;: 313-25.
- Goverdhana S, Puntel M, Xiong W, Zirger JM, Barcia C, Curtin JF, Soffer EB, Mondkar S, King GD, Hu J, Sciascia SA, Candolfi M, Greengold DS, Lowenstein PR, Castro MG. Regulatable gene expression systems for gene therapy applications: Progress and future challenges.2005;: 189-211.
- Haviv YS, Curiel DT. Conditional gene targeting for cancer gene therapy.2001;: 135-54.
- Huang Q, Hu JK, Lohr F, Zhang L, Braun R, Lanzen J, Little JB, Dewhirst MW, Li CY. Heat-induced gene expression as a novel targeted cancer gene therapy strategy.2000;: 3435-9.
- Rubenstrunk A, Trollet C, Orsini C, Scherman D. Positive in vivo heterologous gene regulation by electric pulses delivery with metallothionein I gene promoter.2005;: 1565-72.
- Chastel C, Jiricny J, Jaussi R. Activation of stress-responsive promoters by ionizing radiation for deployment in targeted gene therapy.2004;: 201-15.
- Nuyts S, Van ML, Barbe S, Lammertyn E, Theys J, Landuyt W, Bosmans E, Lambin P, Anne J. Insertion or deletion of the Cheo box modifies radiation inducibility of Clostridium promoters.2001;: 4464-70.
- Datta R, Taneja N, Sukhatme VP, Qureshi SA, Weichselbaum R, Kufe DW. Reactive oxygen intermediates target CC(A/T)6GG sequences to mediate activation of the early growth response 1 transcription factor gene by ionizing radiation.1993;: 2419-22.
- Marples B, Greco O, Joiner MC, Scott SD. Radiogenetic therapy: strategies to overcome tumor resistance.2003;: 2105-12.
- Joki T, Nakamura M, Ohno T. Activation of the radiosensitive EGR-1 promoter induces expression of the herpes simplex virus thymidine kinase gene and sensitivity of human glioma cells to ganciclovir.1995;: 1507-13.
- Takahashi T, Namiki Y, Ohno T. Induction of the suicide HSV-TK gene by activation of the Egr-1 promoter with radioisotopes.1997;: 827-33.
- Wang WD, Chen ZT, Li DZ, Duan YZ, Cao ZH. [Experimental study on lung carcinoma-targeted suicide gene therapy induced by irradiation].2003;: 84-7.
- Wu CM, Li XY, Huang TH. Anti-tumor effect of pEgr-IFNgamma gene-radiotherapy in B16 melanoma-bearing mice.2004;: 3011-5.
- Coulter JA, McCarthy HO, Worthington J, Robson T, Scott S, Hirst DG. The radiation-inducible pE9 promoter driving inducible nitric oxide synthase radiosensitizes hypoxic tumour cells to radiation.2008;: 495-503.
- Jin GH, Jin SZ, Liu Y, Xu RM, Yang JZ, Pan XN, Liu SZ. Therapeutic effect of gene-therapy in combination with local X-irradiation in a mouse malignant melanoma model.2005;: 975-81.
- Scott SD, Joiner MC, Marples B. Optimizing radiation-responsive gene promoters for radiogenetic cancer therapy.2002;: 1396-402.
- Harada K, Ogden GR. An overview of the cell cycle arrest protein, p21(WAF1).2000;: 3-7.
- El-Deiry WS, Tokino T, Velculescu VE, Levy DB, Parsons R, Trent JM, Lin D, Mercer WE, Kinzler KW, Vogelstein B. WAF1, a potential mediator of p53 tumor suppression.1993;: 817-25.
- Worthington J, Robson T, Murray M, O'Rourke M, Keilty G, Hirst DG. Modification of vascular tone using iNOS under the control of a radiation-inducible promoter.2000;: 1126-31.
- McCarthy HO, Worthington J, Barrett E, Cosimo E, Boyd M, Mairs RJ, Ward C, McKeown SR, Hirst DG, Robson T. p21((WAF1))-mediated transcriptional targeting of inducible nitric oxide synthase gene therapy sensitizes tumours to fractionated radiotherapy.2007;: 246-55.
- Espinosa JM, Emerson BM. Transcriptional regulation by p53 through intrinsic DNA/chromatin binding and site-directed cofactor recruitment.2001;: 57-69.
- Nenoi M, Daino K, Ichimura S, Takahash S, Akuta T. Low-dose radiation response of the p21WAF1/CIP1 gene promoter transduced by adeno-associated virus vector.2006;: 553-64.
- Vaupel P, Mayer A. Hypoxia in cancer: significance and impact on clinical outcome.2007;: 225-39.
- Brown JM, Wilson WR. Exploiting tumour hypoxia in cancer treatment.2004;: 437-47.
- Brown JM. Tumor hypoxia in cancer therapy.2007;297-321.
- Kizaka-Kondoh S, Inoue M, Harada H, Hiraoka M. Tumor hypoxia: a target for selective cancer therapy.2003;: 1021-8.
- Dachs GU, Stratford IJ. The molecular response of mammalian cells to hypoxia and the potential for exploitation in cancer therapy.1996;: 126-132.
- Greco O, Patterson AV, Dachs GU. Can gene therapy overcome the problem of hypoxia in radiotherapy?2000;: 201-12.
- Ruan H, Deen DF. Use of hypoxia-regulated gene expression in tumor-specific gene therapy.2001;: 839-43.
- Greco O, Marples B, Joiner MC, Scott SD. How to overcome (and exploit) tumor hypoxia for targeted gene therapy.2003;: 312-25.
- Shibata T, Giaccia AJ, Brown JM. Development of a hypoxia-responsive vector for tumor-specific gene therapy.2000;: 493-8.
- Patterson AV, Williams KJ, Cowen RL, Jaffar M, Telfer BA, Saunders M, Airley R, Honess D, van der Kogel AJ, Wolf CR, Stratford IJ. Oxygen-sensitive enzyme-prodrug gene therapy for the eradication of radiation-resistant solid tumours.2002;: 946-54.
- Scott SD, Greco O. Radiation and hypoxia inducible gene therapy systems.2004;: 269-76.
- Greco O, Joiner MC, Doleh A, Powell AD, Hillman GG, Scott SD. Hypoxia- and radiation-activated Cre/loxP ‘molecular switch’ vectors for gene therapy of cancer.2006;: 206-15.
- Teh BS, guilar-Cordova E, Vlachaki MT, Aguilar L, Mai WY, Caillouet J, Davis M, Miles B, Kadmon D, Ayala G, Lu HH, Chiu JK, Carpenter LS, Woo SY, Grant WH, III, Wheeler T, Thompson TC, Butler EB. Combining radiotherapy with gene therapy (from the bench to the bedside): a novel treatment strategy for prostate cancer.2002;: 458-66.
- Gossen M, Bujard H. Tight control of gene expression in mammalian cells by tetracycline-responsive promoters.1992;: 5547-51.
Language: English
Page range: 115 - 135
Published on: Sep 8, 2008
Published by: Association of Radiology and Oncology
In partnership with: Paradigm Publishing Services
Publication frequency: 4 issues per year
Keywords:
Related subjects:
© 2008 Urska Kamensek, Gregor Sersa, published by Association of Radiology and Oncology
This work is licensed under the Creative Commons License.